Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

TERMINATED

Cognition and Exercise Training

Lead Sponsor:

Montreal Heart Institute

Conditions:

Metabolic Syndrome

Coronary Heart Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The aim of study is to investigate the impact of two different training modalities (high intensity interval training (HIIT) versus moderate intensity continuous exercise training (MICET) on cognitive ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Elderly healthy subjects : with no MetS and no-documented CHD, both males and females, aged\>60 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living.
  • Patients with metabolic syndrome and no-documented CHD, both males and females, aged \> 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. MetS will be defined according to recent updated criteria: presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides \> 1.70 mmol/l, decreased HDL-cholesterol (\< 1.0 mmol/l in men and \< 1.3 mmol/l in women), systolic blood pressure \> 130 mmHg or diastolic blood pressure \> 85 mmHg, and FPG \> 5.6 mmol/l.
  • CHD patients, both males and females, aged \> 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy).
  • Patients with documented stable chronic heart failure will be recruited if they show the following inclusion criteria:
  • ≥18 years
  • Left ventricular ejection fraction (LVEF) \<40% (measured within 6 months of their enrolment by MUGA Scan, echo or radiological ventriculography)
  • NYHA functional class I-III
  • Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation).
  • Able to perform an symptom limited exercise test.
  • Capacity and willingness to sign the informed consent form.
  • Exclusion Criteria:
  • For healthy elderly subjects:
  • age under 60 years
  • lack of expressed written consent
  • metabolic syndrome
  • coronary heart disease
  • chronic systolic heart failure
  • resting left ventricular ejection fraction \< 40 %
  • symptomatic aortic stenosis
  • chronic atrial fibrillation
  • malignant exertional arrhythmias
  • non-cardiopulmonary limitation to exercise (e.g: arthritis or claudication)
  • severe exercise intolerance.
  • For patients with metabolic syndrome:
  • lack of expressed written consent
  • coronary heart disease
  • chronic systolic heart failure
  • resting left ventricular ejection fraction \< 40 %
  • symptomatic aortic stenosis
  • chronic atrial fibrillation
  • malignant exertional arrhythmias
  • non-cardiopulmonary limitation to exercise (e.g: arthritis or claudication)
  • severe exercise intolerance.
  • For patients with CHD
  • lack of expressed written consent
  • recent acute coronary event (\< 3 months)
  • chronic systolic heart failure
  • resting left ventricular ejection fraction \< 40 %
  • symptomatic aortic stenosis
  • severe non-revascularize coronary disease including left main coronary stenosis
  • patient awaiting coronary artery bypass surgery
  • chronic atrial fibrillation
  • presence of permanent ventricular pacemaker
  • malignant exertional arrhythmias
  • non-cardiopulmonary limitation to exercise (e.g: arthritis or claudication)
  • severe exercise intolerance.
  • For CHF patients:
  • Any relative or absolute contraindications to exercise training among patients with stable chronic heart failure according to current recommendations (Working Group on Cardiac Rehabilitation 2001)
  • Fixed-rate pacemaker or ICD devices with heart rate limits set lower than the exercise training target heart rate.
  • Major cardiovascular event of procedure within the 3 months preceding enrolment in the study.
  • Atrial fibrillation
  • Heart failure secondary to significant uncorrected primary valvular disease (except for mitral regurgitation secondary to LV dysfunction)
  • Heart failure secondary to congenital heart disease or obstructive cardiomyopathy.

Exclusion

    Key Trial Info

    Start Date :

    September 1 2013

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 9 2022

    Estimated Enrollment :

    6 Patients enrolled

    Trial Details

    Trial ID

    NCT01906957

    Start Date

    September 1 2013

    End Date

    September 9 2022

    Last Update

    September 14 2022

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Cardiovascular Prevention and Rehabilitation Centre, Montreal Heart Institute

    Montreal, Quebec, Canada, H1T 1N6

    2

    Cardiovascular Prevention and Rehabilitation Centre (EPIC), Montreal Heart Institute

    Montreal, Quebec, Canada, H1T1N6